博碩士論文 992404006 詳細資訊



以作者查詢圖書館館藏 、以作者查詢臺灣博碩士 、以作者查詢全國書目 、勘誤回報 、線上人數：146 、訪客IP：18.118.146.163
姓名 葉建志(Chien-Chih Yeh)  查詢紙本館藏   畢業系所 生命科學系
論文名稱 台灣大腸直腸癌的個案報告及其血管內皮生長因子蛋白家族與接受器之概況
(Case report and the profiles of the vascular endothelial growth factor protein family and its receptors in Taiwan colorectal cancer)
檔案 [Endnote RIS 格式]    [Bibtex 格式]    [相關文章]   [文章引用]   [完整記錄]   [館藏目錄]   [檢視]  [下載]
  1. 本電子論文使用權限為同意立即開放。
  2. 已達開放權限電子全文僅授權使用者為學術研究之目的，進行個人非營利性質之檢索、閱讀、列印。
  3. 請遵守中華民國著作權法之相關規定，切勿任意重製、散佈、改作、轉貼、播送，以免觸法。

摘要(中) 大腸直腸癌目前是國人發生人數最多的癌症，在2012年全世界約有一百四十萬人診斷出罹患大腸直腸癌而且這些個案大多發生於已開發的國家中。根據世界衛生組織的統計資料，在2015年約有七十七萬四千多人死於大腸直腸癌，這高居十大癌症死因的第三名，台灣目前也是如此，2015年台灣每十萬人口平均約24.2人死於大腸直腸癌(男性約27.4人，女性約21人) 。尤其是現在西風東漸，國人的飲食習慣日漸西化，可想而知未來大腸直腸癌一定會更加威脅國人的健康。本論文主要是報告台灣大腸直腸癌特殊及首次發表的個案及針對台灣大腸直腸癌病患其血管內皮生長因子和其接受器(Vascular endothelial growth factor, VEGF and Vascular endothelial growth factor receptor, VEGFR)來進行同步的分析，希望能找出大腸直腸癌各期別的差異性，另外比對腫瘤細胞復發或轉移時的蛋白質變化及病人的存活時間，期望可以找出大腸直腸癌的危險蛋白及使用抗血管新生藥物的指標及預後的參考。第一章是報告一例79歲男性個案，無家族腫瘤史，主要是因腹痛三個月、胃口不佳及體重減輕而求診，經檢查手術後證實為大腸直腸同時三處發生腫瘤的個案，且首次發表出來。第二章是報告一例82歲男性個案因下腹痛持續數周且併有貧血情況求診，經檢查手術後證實為乙狀結腸癌同時伴有闌尾黏液性囊狀腺瘤的個案，這也是很罕見的病況。第三章則是同步分析台灣大腸直腸癌病患其組織及血液五種血管內皮生長因子和三種血管內皮生長因子接受器的變化，我們發現VEGF-A, -B, -C, -D, placental growth factor (PlGF), VEGFR-1, VEGFR-2和VEGFR-3這八種蛋白在腫瘤組織的量都比非腫瘤組織的部位來得高，同時血液中的量也是比健康人高，且轉移性大腸直腸癌病患在其血液及組織中比非轉移性大腸直腸癌病患有較高的VEGF-A, -B, -C, -D, 和PlGF。另外血液中VEGF統計或組織中VEGF及VEGFR陽性人數來比較，主要和病患年紀、腫瘤位置、腫瘤大小、腫瘤期別及淋巴轉移與否有其關聯性，同時VEGF和其結合之VEGFR也存在著正相關，病患有高量的VEGF和VEGFR其存活率會較短。藉由這些資料可以讓我們來根據台灣大腸直腸癌病患其血管內皮生長因子和其接受器的量來判斷其是否有轉移的可能，有利於癌症預後的判別，並決定出適合以VEGF抑制劑來治療大腸直腸癌的標記。
摘要(英) Colorectal cancer (CRC) is a cancer that starts in the colon or rectum. 1.4 million new cases were diagnosed with CRC over the world in 2012 and more than 50 percent of CRC cases occurred in more developed countries. According to the WHO statistics, about 774,000 people died from the CRC in 2015, and this disease is the third most common cause of death worldwide, including Taiwan. In 2015 in Taiwan, 24.2 in 100,000 people (27.4 in 100,000 men and 21.0 in 100,000 women) died from the CRC. This reflects the big impacts of CRC on a country mortality and human health. The overall objective of this dissertation was thus to report new cases in CRC patients living in Taiwan, as well as evaluating the profiles of the vascular endothelial growth factor (VEGF) family and the VEGF receptors (VEGFR) in patients with CRC.
The first chapter indicated a new CRC case on synchronous triple carcinoma of the colon and rectum from a case of a 79-year-old patient who did not have a family history of cancer but had a 3-month history of abdominal pain associated with anemia, loss of appetite, and body weight loss. This was the first case of synchronous triple carcinoma of the colon and rectum found in Taiwan.
The second chapter showed a new CRC case on synchronous mucinous cystadenoma of the appendix (characterized by a cystic dilatation of the appendicular lumen with stasis of mucus inside it) in an 82-year-old patient who had several weeks’ history of low abdominal pain associated with anemia.
The third chapter showed synchronous changes in tissue and circulating protein levels of all the five VEGFs and all the three VEGFRs from Taiwan patients with colorectal carcinoma. VEGF-A, -B, -C, -D, placental growth factor (PlGF), VEGFR-1, VEGFR-2 and VEGFR-3 were higher in tumor tissues than non-tumor tissues. Besides having higher circulating VEGFs and soluble VEGFRs than healthy subjects, metastatic patients exhibited higher VEGF-A, -B, -C, -D and PlGF proteins in both tumor tissue and serum than non-metastatic patients. Besides serum VEGFs, VEGF-positive or VEGFR-positive cases were mainly associated with the age, tumor site, tumor size, tumor stage and lymph node metastasis. Positive correlations between VEGF and VEGFR reflected their specific relationship. Patients exhibiting high levels of VEGF and VEGFR had a shorter overall survival and a less disease-free survival than those with low levels. These data suggest that particular VEGF and VEGFR family members allow discrimination of metastatic CRC from non-metastatic CRC in the studied Taiwanese population and may be possibly used as a marker for gauging the clinical effect of various treatment on the CRC patients.
關鍵字(中) ★ 大腸直腸癌
★ 血管內皮生長因子
★ 轉移
★ 存活率		 關鍵字(英) ★ colorectal cancer
★ vascular endothelial growth factor
★ metastasis
★ overall survival
論文目次 Chinese Abstract ..............................................................................................i
English Abstract .............................................................................................iii
Declaration .....................................................................................................v
Acknowledgments ..........................................................................................vi
Table of Contents ..........................................................................................vii
List of Figures .................................................................................................ix
List of Tables..................................................................................................xii
Abbreviations.................................................................................................xiv
1. General introduction ................................................................................. 1
2. Objective ........................................................................................ 8
3. Chapter One Synchronous triple carcinoma of the colon and rectum ............................................................ 10
Abstract............................................................................................11
Background..................................................................................12
Case report..................................................................................13
Discussion....................................................................................15
Conculsion..................................................................................18
4. Chapter Two Synchronous mucinous cystadenoma of the appendix in a patient with colon cancer ....................................19
Abstract............................................................................................20
Introduction......................................................................................21
Case report..................................................................................22
Discussion........................................................................................24
Conclusion..........................................................................................27
5. Chapter Three Protein expression profiling of the vascular endothelial growth factor family and its receptors in Taiwan colorectal cancer ...........................................28
Abstract................................................................................................29
Introduction......................................................................................... 31
Materials and Methods....................................................................... 35
Results........................................................................................39
Discussion.......................................................................................46
6. General conclusions.............................................................................52
7. Refferences..........................................................................................53
8. Appendixes…............................................................................................103


參考文獻 1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A, Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108.
2. World Health Organization Fact sheets: Cancer. February 2017. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/
3. Ministry of Health and Welfare, Taiwan. Taiwan Health and Welfare Report 2016. Available at: https://www.mohw.gov.tw/cp-137-521-2.html.
4. Connell W. PRO: Endoscopic surveillance minimizes the risk of cancer. Am J Gastroenterol 2004; 99(9): 1631–1633.
5. Brenner H, Hoffmeister M, Arndt V, Stegmaier C, Altenhofen L, Haug U.Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst. 2010;102(2): 89–95.
6. Haug U, Hundt S, Brenner H. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am J Gastroenterol. 2010;105(3):682–690.
7. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, Dash C, Giardiello FM, Glick S, Levin TR, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58(3):130–160.
8. Schulmann K, Reiser M, Schmiegel W. Colonic cancer and polyps. Best Pract Res Clin Gastroenterol. 2002;16(1):91–114.
9. Folkman J.What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4–6.
10. Rifkin DB, Moscatelli D. Recent developments in the cell biol- ogy of basic fibroblast growth factor. J Cell Biol 1989; 109: 1-6.
11. Nicosia RF, Nicosia SV, Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis In vitro. Am J Pathol 1994; 145: 1023-1029.
12. Takahashi Y, Bucana CD, Liu W et al. Platelet-derived endothe- lial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 1996; 88: 1146-1151.
13. Jouanneau J, Moens G, Montesano R et al. FGF-1 but not FGF- 4 secreted by carcinoma cells promotes in vitro and in vivo angiogenesis and rapid tumor proliferation. Growth Factors 1995; 12: 37-47.
14. Suri C, McClain J, Thurston G et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998; 282: 468-471.
15. Pepper MS, Vassalli JD, Orci L et al. Biphasic effect of trans- forming growth factor-beta 1 on in vitro angiogenesis. Exp Cell Res 1993; 204: 356-363.
16. Gleave ME, Hsieh JT, Wu HC et al. Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma. Cancer Res 1993; 53: 5300-5307.
17. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 851-858.
18. Leung DW, Cachianes G, Kuang WJ et al. Vascular endothe- lial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309.
19. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5: 1359-1364.
20. Korpanty G, Sullivan LA, Smyth E, Carney DN, Brekken RA. Molecular and clinical aspects of targeting the VEGF pathway in tumors. J Oncol. 2010; 2010: 652320.
21. Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A. 1998; 95(20): 11709–11714.
22. Li X, Lee C, Tang Z, et al. VEGF-B: a survival, or an angiogenic factor? Cell Adh Migr. 2009; 3(4): 322–327.
23. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004; 5: 74-80.
24. Baldwin ME, Halford MM, Roufail S, Williams RA, Hibbs ML, Grail D, et al. Vascular endothelial growth factor D is dispensable for development of the lym- phatic system. Mol Cell Biol 2005; 25:2441-2449.
25. Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis. 2008; 11(3): 215–221.
26. Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull. 2011; 34(12):1785–1788.
27. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal. 2009; 2(59):re1.
28. C. Fischer, M. Mazzone, B. Jonckx, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer. 2008;8(12):942–956.
29. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A 1998; 95: 9349–9354.
30. Bates RC, Goldsmith JD, Bachelder RE, Brown C, Shibuya M, Oettgen P, Mercurio AM. Flt-1-dependent survival characterizes the epithelialmesenchymal transition of colonic organoids. Curr Biol 2003; 13:1721–1727.
31. Yi ZY, Feng LJ, Xiang Z, Yao H. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in hepatocellular carcinoma cells. J Invest Surg 2011; 24: 67–76.
32. Shintani S, Li C, Ishikawa T, Mihara M, Nakashiro K, Hamakawa H. Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma. Oral Oncol 2004; 40: 13–20.
33. Gunningham SP, Currie MJ, Han C, Robinson BA, Scott PA, Harris AL, Fox SB.VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. J Pathol 2001; 193:325–332.
34. Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, Lorentz P, Jeltsch M, Alitalo K, Eriksson U, Christofori G, Pietras K. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS One 2010; 5:e14109.
35. Hamerlik P, Lathia JD, Rasmussen R, et al. Autocrine VEGF-VEGFR2- Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med. 2012; 209(3):507–520.
36. Millauer, B., Wizigmann-Voos, S., Schnurch, H., Martinez, R., Moller, N. P., Risau, W. and Ullrich, A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72, 835–846.
37. Quinn, T. P., Peters, K. G., De Vries, C., Ferrara, N. and Williams, L. T. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc. Natl. Acad. Sci. U.S.A.1993; 90, 7533–7537.
38. Oelrichs, R. B., Reid, H. H., Bernard, O., Ziemiecki, A. and Wilks, A. F. NYK/FLK-1: a putative receptor protein tyrosine kinase isolated from E10 embryonic neuroepithelium is expressed in endothelial cells of the developing embryo. Oncogene 1993; 8, 11–18.
39. Holmqvist, K. et al. The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J. Biol. Chem. 2004; 279, 22267–22275 .
40. Dayanir, V., Meyer, R. D., Lashkari, K. & Rahimi, N. Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation. J. Biol. Chem. 2001; 276, 17686–17692 .
41. Makinen, T. et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 2001; 20, 4762–4773.
42. Wang, J. F., Zhang, X. & Groopman, J. E. Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress. J. Biol. Chem. 2004; 279, 27088–27097.
43. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA. 1993; 90(22): 10705-10709.
44. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350(7): 672-683.
45. Di Marco GS, Reuter S, Hillebrand U, et al. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol. 2009; 20(10): 2235-2245.
46. Duda DG, Willett CG, Ancukiewicz M, et al. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation inlocally advanced rectal cancer. Oncologist. 2010; 15(6): 577-583.
47. Albuquerque RJ, Hayashi T, Cho WG, et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med. 2009; 15(9): 1023-1030.
48. Becker J, Pavlakovic H, Ludewig F, et al. Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2. Clin Cancer Res. 2010; 16(5): 1431-1441.
49. Shibata MA, Ambati J, Shibata E, Albuquerque RJ, Morimoto J, Ito Y, Otsuki Y. The endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model. BMC Med. 2010; 8: 69.
50. Singh N, Tiem M, Watkins R, et al. Soluble vascular endothelial growth factor receptor-3 is essential for corneal alymphaticity. Blood. 2013; 121(20): 4242-4249.
51. Kendall RL, wang G and Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. biochem biophys Res Commun 1996; 226; 324-328.
52. Harris AL, Reusch P, barlenon b, Hang C, Dobbs N and Marme D. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. clin cancer res 2001; 7: 1992-1997.
53. Toi M, Bando H, ogawa t, Muta M, Horing c and Weich HA. Significance of vascular endothelial growth factor (VEGF)/ soluble VegF receptor-1 relationship in breast cancer. Int J Cancer 2002; 98: 14-18.
54. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V and Topuz E. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res 2006; 16: 405-411.
55. Yamaguchi t, nando H, Mori t, et al. Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: association with progression and prognosis. cancer sci 2007; 98: 405-410.
56. Hu Q, Dey AL, Yang Y, et al. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myeloidysplastic syndromes. Cancer 2004; 100: 1884-1891.
57. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Comm. 2005; 333(2): 328–335.
58. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab (rhuMAb VEGF) to bolus IFL in the first-line treatment of patients with metastatic colorectal cancer: Results of a randomized phase III trial. N Engl J Med 2004; 350: 2335-2342.
59. U. S. Food and Drug Administration. Center for Drug Evaluation and Research. Final Labeling Text, BL125085 Supplement, 2008.
60. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
61. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005; 23: 4866-4875.
62. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010 Jan 20; 28(3): 453-9.
63. Samant RS, Shevde LA. Recent advances in anti-angiogenic therapy of cancer. Oncotarget. 2011; 2(3): 122–134.
64. Chu E. An update on the current and emerging targeted agents in meta- static colorectal cancer. Clin Colorectal Cancer. 2012; 11(1): 1–13.
65. Lee TK, Barringer M, Myers RT, Sterchi JM: Multiple primary carcinomas of the colon and associated extracolonic primary malignant tumors. Ann Surg 1982, 195:501-507.
66. Sakellaridis T, Mathioulakis S, Antiochos C: Synchronous early primary adenocarcinoma of both rectum and gallbladder. Report of a case. IntSem Surg Oncol : ISSO 2005, 2:19.
67. Arai T, Sawabe M, Takubo K, Kanazawa K, Esaki Y: Multiple colorectal cancers in the elderly: a retrospective study of both surgical and autopsy cases. J Gastroenterol 2001, 36:748-752.
68. Cunliffe WJ, Hasleton PS, Tweedle DE, Schofield PF: Incidence of synchronous and metachronous colorectal carcinoma. British J Surg 1984, 71:941-943.
69. Takeuchi H, Toda T, Nagasaki S, Kawano T, Minamisono Y, Maehara Y, Sugimachi K: Synchronous multiple colorectal adenocarcinomas. J Surg Oncol 1997, 64:304-307.
70. Chen HS, Sheen-Chen SM: Synchronous and "early" metachronous colorectal adenocarcinoma: analysis of prognosis and current trends. Dis Colon Rectum 2000, 43:1093-1099.
71. Ueno M, Muto T, Oya M, Ota H, Azekura K, Yamaguchi T: Multiple primary cancer: an experience at the Cancer Institute Hospital with special reference to colorectal cancer. Int J Clin Oncol 2003, 8:162-167.
72. Wang HZ, Huang XF, Wang Y, Ji JF, Gu J: Clinical features, diagnosis, treatment and prognosis of multiple primary colorectal carcinoma. World J Gastroenterol 2004, 10:2136-2139.
73. Evers BM, Mullins RJ, Matthews TH, Broghamer WL, Polk HC, Jr.: Multiple adenocarcinomas of the colon and rectum. An analysis of incidences and current trends. Dis Colon Rectum 1988, 31:518-522.
74. Greenstein AJ, Slater G, Heimann TM, Sachar DB, Aufses AH, Jr.: A comparison of multiple synchronous colorectal cancer in ulcerative colitis, familial polyposis coli, and de novo cancer. Ann Surg 1986, 203:123-128.
75. Papadopoulos V, Michalopoulos A, Basdanis G, Papapolychroniadis K, Paramythiotis D, Fotiadis P, Berovalis P, Harlaftis N: Synchronous and metachronous colorectal carcinoma. Techniq Coloproctol 2004, 8 Suppl 1:s97-s100.
76. Howard ML, Greene FL: The effect of preoperative endoscopy on recurrence and survival following surgery for colorectal carcinoma. American Surgeon 1990, 56:124-127.
77. Martinez SA, Hellinger MD, Martini M, Hartmann RF: Intraoperative endoscopy during colorectal surgery. Surg Laparoscopy Endoscopy 1998, 8:123-126.
78. Torralba JA, Robles R, Parrilla P, Lujan JA, Liron R, Pinero A, Fernandez JA: Subtotal colectomy vs. intraoperative colonic irrigation in the management of obstructed left colon carcinoma. Dis Colon Rectum 1998, 41:18-22.
79. Vining DJ, Gelfand DW, Bechtold RE, Scharling ES, Grishaw EK, Shifrin RY: Technical feasibility of colonimaging with helical CT and virtual reality. AJR Am J Roentgenol 1994, 162 (suppl):104.
80. Luboldt W, Bauerfeind P, Steiner P, Fried M, Krestin GP, Debatin JF: Preliminary assessment of three-dimensional magnetic resonance imaging for various colonic disorders. Lancet 1997, 349:1288–1291.
81. De Haan MC, Halligan S, Stoker J: Does CT colonography have a role for population-based colorectal cancer screening? Eur Radiol 2012, 22:1495-1503.
82. Mantellini P, Mungai F, Menchi I, Villari N, Mascalchi M: CT colonography after incomplete colonoscopy in subjects with positive faecal occult blood test. World J Gastroenterol 2008, 14: 4499-4504.
83. Nagata K, Endo S, Tatsukawa K, Kudo SE: Double colorectal cancer only diagnosed by computed tomographic colonography. Case Rep Gastroenterol 2008, 2:44-48.
84. Maras-Simunic M, Druzijanic N, Simunic M, Roglic J, Tomic S, Perko Z: Use of modified multidetector CT colonography for the evaluation of acute and subacute colon obstruction caused by colorectal cancer: a feasibility study. Dis Colon Rectum. 2009, 52:489-495.
85. Frank M. Zijta , Shandra Bipat, Jaap Stoker: Magnetic resonance (MR) colonography in the detection of colorectal lesions: a systematic review of prospective studies. Eur Radiol 2010, 20:1031–1046.
86. Sun L, Wu H, Guan YS: Colonography by CT, MRI and PET/CT combined with conventional colonoscopy in colorectal cancer screening and staging. World J Gastroenterol 2008, 14:853-863.
87. Nagata K, Kudo S-E: Triple colon cancer successfully demonstrated by CT air-contrast enema. Dig Surg 2004, 21:10-11.
88. Nagata K, Ota Y, Okawa T, Endo S, Kudo SE: PET/CT colonography for the preoperative evaluation of the colon proximal to the obstructive colorectal cancer. Dis Colon Rectum 2008, 51:882-890.
89. Kinner S, Antoch Gch P: Whole-body PET/CT-colonography: a possible new concept for colorectal cancer staging. Abdom Imaging 2007, 32:606-612.
90. Veit-Haibach P, Kuehle CA, Beyer T, Stergar H, Kuehl H, Schmidt J, Börsch G, Dahmen G, Barkhausen J, Bockisch A, Antoch G.: Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA 2006, 296:2590-2600.
91. Lillehei RC, Wangensteen OH: Bowel function after colectomy for cancer, polyps, and diverticulitis. J Amer Med Assoc 1955, 159:163-170.
92. Rosenthal I, Baronofsky ID: Prognostic and therapeutic implications of polyps in metachronous colic carcinoma. J Amer Med Assoc 1960, 172:37-41.
93. Easson AM, Cotterchio M, Crosby JA, Sutherland H, Dale D, Aronson M, Holowaty E, Gallinger S: A population-based study of the extent of surgical resection of potentially curable colon cancer. Ann Surg Oncol 2002, 9:380-387.
94. Anderson BB: Synchronous cancer of the colon: a case for more definitive resection in colon cancer. J Natl Med Assoc 1978, 70:583-584.
95. Tsantilas D, Ntinas A, Petras P, Zambas N, Al Mogrambi S, Frangandreas G, Spyridis C, Gerasimidis T: Metachronous colorectal adenocarcinomas. Techniq Coloproctol 2004, 8 Suppl 1:s202-204.
96. Passman MA, Pommier RF, Vetto JT: Synchronous colon primaries have the same prognosis as solitary colon cancers. Dis Colon Rectum 1996, 39:329-334.
97. Sierra-Montenegro E, Sierra-Luzuriaga G, Leone-Stay G, et al. Mucinous cystadeoma of the appendix: case Report. Cir Cir. 2010;78:255–8.
98. Yakan S, Caliskan C, Uguz A, et al. A retrospective study on mucocele of the appendix presented with acute abdomen or acute appendicitis. Hong Kong J Emerg Med. 2011;18:144–9.
99. Rampone B. Giant appendiceal mucocele: report of a case and brief review. World J Gastroenterol. 2005;11:4761–3.
100. Khan MN, Moran BJ. Four percent of patients undergoing colorectal cancer surgery may have synchronous appendiceal neoplasia. Dis Colon Rectum 2007;50:1856-9.
101. Lyda MH, Noffsinger A, Belli J, et al. Multifocal neoplasia involving the colon and appendix in ulcerative colitis: pathological and molecular features. Gastroenterology. 1998;115:1566-73..
102. Ruiz-Tovar J, Teruel DG, Castiñeiras VM, et al. Mucocele of the appendix. World J Surg. 2007; 31:542–8.
103. Higa E, Rosai J, Pizzimbono CA, et al. Mucosal hyperplasia, mucinous cystadenoma, and mucinous cystadenocarcinoma of the appendix. A re-evaluation of appendiceal “mucocele”. Cancer. 1973;326:1525―41.
104. Pai RK, Longacre TA. Appendiceal mucinous tumors and pseudomyxoma peritonei: histologic features, diagnostic problems, and proposed classifi¬cation. Adv Anat Pathol. 2005;12: 291–311.
105. Aho AJ, Heinonen R, Lauren P. Benign and malignant mucocele of the ap¬pendix. Acta Chir Scand. 1973;139:392–400.
106. Dhage-Ivatury S, Sugarbaker PH. Update on the surgical approach to mucocele of the appendix. J Am Coll Surg. 2006;202(4):680-4.
107. Aghahowa EJ, Bharati D, Al-Adwani M. Appendicular mucocele—a case report. Kuwait Med J. 2008;40:78–80.
108. Bartlett C, Manoharan M, Jackson A. Mucocele of the appendix—a diagnostic dilemma: a case report. J Med Case Rep. 2007;19:183.
109. Kim SH, Lim HK, Lee WJ, et al. Mucocele of the appendix: ultrasonographic and CT findings. Abdom Imaging. 1998;23(3):292-6.
110. Zissin R, Gayer G, Kots E, et al. Imaging of mucocoele of the appendix with emphasis on the CT findings: a report of 10 cases. Clin Radiol. 1999;54:826–32.
111. Madwed D, Mindelzun R, Jeffrey RB Jr. Mucocele of the appendix: imaging findings. Am J Roentgenol. 1992;159:69–72.
112. Lau H, Yuen WK, Loong F, et al. Laparoscopic resection of an appendiceal mucocele. Surg Laparosc Endosc Percutan Tech. 2002;12:367–70.
113. Soweid AM, Clarkston WK, Andrus CH, et al. Diagnosis and management of appendiceal mucoceles. Dig Dis. 1998;16:183-6.
114. Khan M, Ahmed R, Saleem T. Intricacies in the surgical management of appendiceal mucinous cystadenoma: a case report and review of the literature. J Med Case Rep. 2010;4:129.
115. Chiu CC, Wei PL, Huang MT, et al. Laparoscopic resection of appendiceal mucinous cystadenoma. J Laparoendosc Adv Surg Tech A. 2005;15:325-8.
116. Williams RA, Meyers P. Pathology of the appendix. Chapman & Hall Medical, New York, 1994.
117. Korpanty G, Sullivan LA, Smyth E, Carney DN, Brekken RA. Molecular and clinical aspects of targeting the VEGF pathway in tumors. J Oncol. 2010;2010: 652320.
118. Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjänen S, Syrjänen K, Collan Y, Pyrhönen S. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res. 2008;28(6B):3865-70.
119. Pavlidis ET, Pavlidis TE. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. World J Gastroenterol. 2013;19(31):5051-60.
120. Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol. 2003;200(2):183-94.
121. Witte D, Thomas A, Ali N, Carlson N, Younes M. Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res. 2002;22(3):1463-6.
122. Martins SF, Garcia EA, Luz MA, Pardal F, Rodrigues M, Filho AL. Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. Cancer Genomics Proteomics. 2013;10(2):55-67.
123. White JD, Hewett PW, Kosuge D, McCulloch T, Enholm BC, Carmichael J, Murray JC. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res. 2002;62(6):1669-75.
124. Hu WG, Li JW, Feng B, Beveridge M, Yue F, Lu AG, Ma JJ, Wang ML, Guo Y, Jin XL, Zheng MH. Vascular endothelial growth factors C and D represent novel prognostic markers in colorectal carcinoma using quantitative image analysis. Eur Surg Res. 2007;39(4):229-38.
125. Kemık O, Sarbay Kemık A, Sümer A, Purısa S, Tükenmez B, Tüzün S. Preoperative serum placenta growth factor level as a new marker for stage II or III colorectal cancer patients. Turk J Gastroenterol. 2012;23(2):104-9.
126. Sung CY, Son MW, Ahn TS, Jung DJ, Lee MS, Baek MJ. Expression of placenta growth factor in colorectal carcinomas. J Korean Soc Coloproctol. 2012; 28(6): 315-20.
127. Tsai HL, Lin CH, Huang CW, Yang IP, Yeh YS, Hsu WH, Wu JY, Kuo CH, Tseng FY, Wang JY. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients. Int J Clin Exp Pathol. 2015;8(2):1900-10.
128. Wei SC, Tsao PN, Yu SC, Shun CT, Tsai-Wu JJ, Wu CH, Su YN, Hsieh FJ, Wong JM. Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut. 2005;54(5):666-72.
129. Wei SC, Liang JT, Tsao PN, Hsieh FJ, Yu SC, Wong JM. Preoperative serum placenta growth factor level is a prognostic biomarker in colorectal cancer. Dis Colon Rectum. 2009;52(9):1630-6.
130. Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull. 2011; 34 (12): 1785-1788.
131. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer. 2008;8(12):942-956.
132. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M, Alitalo K, Eriksson U. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A. 1998;95(20): 11709-11714.
133. Li X, Lee C, Tang Z, Zhang F, Arjunan P, Li Y, Hou X, Kumar A, Dong L. VEGF-B: a survival, or an angiogenic factor? Cell Adh Migr. 2009;3(4):322–327.
134. Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis. 2008;11(3): 215-221.
135. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, Betsholtz C, Alitalo K. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004;5(1): 74-80.
136. Baldwin ME, Halford MM, Roufail S, Williams RA, Hibbs ML, Grail D, Kubo H, Stacker SA, Achen MG. Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol Cell Biol. 2005;25(6):2441-2449.
137. Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer TW, Somcio RJ, Wu Y, Hooper A, Hicklin DJ, Ellis LM. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene. 2005;24(16):2647-53.
138. Yamaguchi T, Bando H, Mori T, Takahashi K, Matsumoto H, Yasutome M, Weich H, Toi M. Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: association with progression and prognosis. Cancer Sci. 2007;98(3):405-410.
139. Wei SC, Tsao PN, Weng MT, Cao Z, Wong JM. Flt-1 in colorectal cancer cells is required for the tumor invasive effect of placental growth factor through a p38-MMP9 pathway. J Biomed Sci. 2013;20:39.
140. Hewitt S, Robinowitz M, Bogen S, Gown A, Kalra K, et al. (2011) Quality Assurance for Design Control and Implementation of Immunohistochemistry Assays; Approved Guideline – Second Edition, CLSI Document I/LA28-A2. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute.
141. Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, Tam L, Munro AF, Dunne B, Bartlett JM: Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 2006, 48: 787–794.
142. Tuominen VJ, Ruotoistenmaki S, Viitanen A et al: ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 12(4): R56, 2010.
143. Ruifrok AC and Johnston DA: Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 23(4): 291-299, 2001.
144. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab (rhuMAb VEGF) to bolus IFL in the first-line treatment of patients with metastatic colorectal cancer: Results of a randomized phase III trial. N Engl J Med. 2004;350:2335-2342.
145. U. S. Food and Drug Administration. Center for Drug Evaluation and Research. Final Labeling Text, BL125085 Supplement, 2008.
146. Kazazi-Hyseni F, Beijnen JH, and Schellens JHM. Bevacizumab. Oncologist. 2010;15(8):819-825.
147. Wang K, Stark FS, Schlothauer T, Lahr A, Cosson V, Zhi J, Habben K, Tessier J, Schick E, Staack RF, Krieter O. An apparent clinical pharmacokinetic drug-drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism. Cancer Chemother Pharmacol. 2017;79(4):661-671.
148. Lee SJ, Lee SY, Lee WS, Yoo JS, Sun JM, Lee J, Park SH, Park JO, Ahn MJ, Lim HY, Kang WK, Park YS. Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. Invest New Drugs. 2017;doi: 10.1007/s10637-017-0463-y. [Epub ahead of print]
149. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol. 2004;22(2):229-237.
150. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Cartenì G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E, Montemurro S, Cramarossa A, Lorusso V, Di Bisceglie M, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunato S, Mancarella S, Brunetti C; Gruppo Oncologico Dell′Italia Meridionale. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol. 2005;23(22):4866-4875.
151. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010;28(3):453-9.
152. Tsai HL, Lin CH, Huang CW, Yang IP, Yeh YS, Hsu WH, Wu JY, Kuo CH, Tseng FY, Wang JY. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients. Int J Clin Exp Pathol. 2015;8(2):1900-10.
153. Samant RS, Shevde LA. Recent advances in anti-angiogenic therapy of cancer. Oncotarget. 2011;2(3):122-134.
154. Chu E. An update on the current and emerging targeted agents in meta- static colorectal cancer. Clin Colorectal Cancer. 2012;11(1):1-13.
155. Bates RC, Goldsmith JD, Bachelder RE, Brown C, Shibuya M, Oettgen P, Mercurio AM. Flt-1-dependent survival characterizes the epithelialmesenchymal transition of colonic organoids. Curr Biol. 2003;13:1721–1727.
156. Holmqvist K, Cross MJ, Rolny C, Hägerkvist R, Rahimi N, Matsumoto T, Claesson-Welsh L, Welsh M. The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem. 2004;279(21):22267–22275 .
157. Dayanir V, Meyer RD, Lashkari K, Rahimi N. Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation. J Biol Chem. 2001;276(21): 17686-17692 .
158. Mäkinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, Wise L, Mercer A, Kowalski H, Kerjaschki D, Stacker SA, Achen MG, Alitalo K. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 2001;20(17):4762-4773.
159. Wang JF, Zhang X, Groopman JE. Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress. J Biol Chem. 2004;279(26):27088-27097.
指導教授 高永旭 褚志斌(Yung-Hsi Kao Chih-Pin Chuu) 審核日期 2018-1-25
推文 facebook   plurk   twitter   funp   google   live   udn   HD   myshare   reddit   netvibes   friend   youpush   delicious   baidu   
網路書籤 Google bookmarks   del.icio.us   hemidemi   myshare   

若有論文相關問題，請聯絡國立中央大學圖書館推廣服務組 TEL:(03)422-7151轉57407，或E-mail聯絡  - 隱私權政策聲明